Comparative Pharmacology
Head-to-head clinical analysis: KLEBCIL versus LEDERCILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLEBCIL versus LEDERCILLIN VK.
KLEBCIL vs LEDERCILLIN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Penicillin V is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms during the active growth phase.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
Terminal elimination half-life is 0.5 hours (range 0.4–0.6 hours) in adults with normal renal function. In severe renal impairment (CrCl <10 mL/min), half-life extends to ~4 hours.
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Renal elimination predominantly via tubular secretion of unchanged drug (>90% of absorbed dose). Approximately 20-40% of an oral dose is recovered in urine as unchanged penicillin V. Biliary excretion accounts for <1% of elimination; fecal elimination is negligible.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic